Histologic type definition in clinical trials on advanced non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 6, Issue 2, 2011, Pages 405-

  Rossi, Giulio ^a   Cavazza, Alberto ^b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b S MARIA NUOVA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; PACLITAXEL; PEMETREXED;

ADD ON THERAPY; CANCER CLASSIFICATION; CARCINOID; CYTOLOGY; DRUG EFFICACY; HISTOLOGY; HUMAN; LARGE CELL CARCINOMA; LETTER; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR DIFFERENTIATION;

EID: 79551558093     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31820b9e0e     Document Type: Letter

References (5)

1. Sandler A, Yi J, Dahlberg S, et al. Treatment outcomes by tumor histology in eastern cooperative group study E4599 of bavacizumab with paclitaxel/carboplatin for advanced nonsmall cell lung cancer. J Thorac Oncol 2010;5:1416-1423.
2. Neal JW. Histology matters: individualizing treatment in non-small cell lung cancer. Oncologist 2010;15:3-5.
3. Brambilla E. Lung cancer: multidisciplinary approach for management: cell and molecular biology assembly contribution to the celebration of 20 years of the ERS. Eur Respir J 2010;35:717-720.
4. Klein R, Wielage R, Muehlenbein C, et al. Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol 2010;5:1263-1272.
5. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.